EGFR and non-small cell lung carcinoma: The advent of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) has significantly improved survival outcomes in patients with advanced EGFR‐mutated non‐small cell lung cancer (NSCLC).